Skip to main content
SpringerLink
Log in

Clinical Experience

Platinum and Taxanes

  • Chapter
Book cover Platinum-Based Drugs in Cancer Therapy

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

  • 295 Accesses

Abstract

The platinum drugs are widely used in cancer therapy. In recent years they have been successfully combined with the taxanes, especially for the treatment of patients with cancers of the ovary, lung, breast, and head and neck. This chapter presents some of the evidence on the use of platinum and taxane regimens in these malignancies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

Ovarian Cancer

  1. Abu-Rustum, N. R., Aghajanian, C., Borakat, R. R., Fenelly, D., Shapiro, F., and Spriggs, D. (1997) Salvage weekly paclitaxel in recurrent ovarian cancer. Semin. Oncol. 24(Suppl 15), S15–62—S15–67.

    Google Scholar 

  2. Advanced Ovarian Cancer Trialist Group (1991) Chemotherapy in advanced ovarian cancer: an overview of randomized clinical trials. BMJ 303, 884–893.

    Google Scholar 

  3. Alberts, P. S., Green, S. Hannigan, E. V.,(1992) Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III, randomized trial in stages III and IV ovarian cancer. J. Clin. Oncol. 10, 706–717.

    PubMed  CAS  Google Scholar 

  4. Bella, M., Cocconi, G., and Lotticci, R. (1994) Mature results of a prospective randomized trial comparing two different dose-intensity regimens of cisplatin in advanced ovarian carcinoma. Ann. Oncol. 5 (Suppl 80), 2.

    Google Scholar 

  5. Bertelsen, K., Jakobsen, A., Stroyer, I., (1993) A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, Adriamycin and cisplatin in advanced epithelial ovarian cancer. A Danish Ovarian Study Group trial (DaCOVA). Gynecol. Oncol. 49, 30–35.

    Google Scholar 

  6. Blockledge, G., Lawton, F., Redman, C., and Kelly, K. (1989) Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br. J. Cancer 59, 650–653.

    Google Scholar 

  7. Bolis, G., Scarfone, G., Villa, A., Acerboni, S., Siliprandi, V., and Guarnerio (1997) A phase I trial with fixed dose carboplatin and escalating doses of paclitaxel in advanced ovarian cancer. Semin. Oncol. 24(Suppl 2), S2–23—S2–25.

    Google Scholar 

  8. Bookman, M. A., McGuire, W. P., Kilpatrick, D.,(1996) Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. J. Clin. Oncol. 14, 1895–1902.

    Google Scholar 

  9. Calvert, A. H. (1997) A review of the pharmacokinetics and pharmacodynamics of combination carboplatin/paclitaxel. Semin. Oncol. 24(Suppl 2), S2–85-S2–90.

    Google Scholar 

  10. Calvert, A. H., Newell, D. R., Gumbrell, L. A.,(1989) Carboplatin dosage: evaluation of a simple formula based on renal function. J. Clin. Oncol. 7, 1748–1756.

    Google Scholar 

  11. Capri, G., Tarenzi, E., Fulfaro, F., and Gianni, L. (1996) The role of taxanes in the treatment of breast cancer. Semin. Oncol. 23 (Suppl 2), 68–75.

    PubMed  CAS  Google Scholar 

  12. Chevallier, B. Fumoleau, P., Kerbrat, P.,(1995) Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer. A phase II trial of the Clinical Screening Cooperative Group of the European Organisation for Research and Treatment of Cancer. J. Clin. Oncol. 13 314–322.

    Google Scholar 

  13. Donehower, R. C., Rowinsky, E. K., Grochow, L. K.,(1987) Phase I trial of taxol in patients with advanced cancer. Cancer Treat. Rep. 71, 1–7.

    Google Scholar 

  14. du Bois, A., Luck, H., Meier, W.,(1997) Carboplatin/paclitaxel versus cisplatin paclitaxel as first line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer Study Group. Semin. Oncol. 24(Suppl 15), S15 44-S15–52.

    Google Scholar 

  15. Einzig, A. I., Wiernik, P. H., Sasloff, J.,(1992) Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J. Clin. Oncol. 10, 1748–1753.

    Google Scholar 

  16. Eisenhauer, E. A., ten Bokkel Huinink, W. W., Swenerton, K. D.,(1994) European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high dose versus low dose and long versus short infusion. J. Clin. Oncol. 12, 2654–2666.

    PubMed  CAS  Google Scholar 

  17. Eisenhauer, E. A., Vermokken, J. B., and van Glabbeke, M. (1997) Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivarate analysis of 704 patients. Ann. Oncol. 8, 963–968.

    PubMed  CAS  Google Scholar 

  18. Gelmon, K. (1994) The taxoids: paclitaxel and docetaxel. Lancet 344, 1267–1272.

    PubMed  CAS  Google Scholar 

  19. Gianni, L., Kearns, C. M., Giani, A.,(1995) Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J. Clin. Oncol. 13, 180–190.

    PubMed  CAS  Google Scholar 

  20. Gore, M. E. (1996) The role of taxanes, in Ovarian Cancer 4, Chapman & Hall Medical, London, pp. 143–152

    Google Scholar 

  21. Gore, M. E., Fryatt, I., Wiltshaw, E., and Dawson, T. (1990) Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol. Oncol. 36, 207–211.

    PubMed  CAS  Google Scholar 

  22. Gore, M. E., Levy, V., Rustin, G.,(1995) Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience. Br. J. Cancer 72, 1016–1019.

    PubMed  CAS  Google Scholar 

  23. Gore, M. E., Preston, N., and A’Hern, R. P. (1995) Platinum-taxol non-cross resistance in epithetial ovarian cancer. Br. J. Cancer 71, 1308–1310.

    PubMed  CAS  Google Scholar 

  24. Greco, F. A. and Hainsworth, J. D. (1996) Paclitaxel via 1-hour infusion: rationale and pharmocology. Semin. Oncol. 23 (Suppl 15), 19–20.

    PubMed  CAS  Google Scholar 

  25. Gruppo Interregionale Cooperativo Oncologica Ginecologica (1992) Long term results of a randomized trial comparing cisplatin with cisplatin and cyclophosphamide with cisplatin, cyclophosphamide and Adriamycin in advanced ovarian cancer. Gynecol. Oncol. 45, 115–117.

    Google Scholar 

  26. Hakes, T., Hoskins, W., Jones, W.,(1992) Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin and cisplatin in advanced ovarian cancer. Gynecol. Oncol. 45, 284–289.

    PubMed  CAS  Google Scholar 

  27. Harper, P. (1997). ICON2 and ICON3 data in previously untreated ovarian cancer: results to date. Semin. Oncol. 24(Supp1.15), S15–23-S15–25.

    Google Scholar 

  28. Huizing, M. T., Van Warmerdam, L. J. C., Rosing, H.,(1997) Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer. J. Clin. Oncol. 15, 1953–1964.

    PubMed  CAS  Google Scholar 

  29. Kaye, S. B., Piccart M., Aapro, M., Francis, P. and Kavanagh, J. (1997) Phase II trials of docetaxel (Taxotere ®) in advanced ovarian cancer-an updated overview. Eur. J. Cancer. 33, 2167–2170.

    PubMed  CAS  Google Scholar 

  30. Kaye, S. D., Lewis, C. R., Paul, J.,(1992) Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet 340, 329–333.

    PubMed  CAS  Google Scholar 

  31. Lavelle, F., Bissery, M. C., Combeau, C.,(1995) Preclinical evaluation of docetaxel (Taxotere). Semin. Oncol. 22 (Suppl 4), 3–16.

    CAS  Google Scholar 

  32. Mainwaring, P. N., and Gore, M. E. (1995) The importance of dose and schedule in cancer chemotherapy: epithelial ovarian cancer. Anticancer Drugs. 6 (Suppl 5), 29–41.

    PubMed  Google Scholar 

  33. Markman, M. (1997) Current status and future directions of platinum/paditaxel-based chemotherapy of ovarian cancer. Semin. Oncol. 24(Suppl 11), S11–24-S11–27.

    Google Scholar 

  34. Markman, M., Rothman, R., Hakes, T.,(1991) Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J. Clin. Oncol. 9, 389–393.

    PubMed  CAS  Google Scholar 

  35. McGuire, W. P., Hoskins, W. J., Brady, M. F.,(1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334, 1–6.

    PubMed  CAS  Google Scholar 

  36. Muggia, T. M., Brady, P. S., Braly, M. F.,(1997) Phase II of cisplatin (P) or paclitaxel (T), versus their combination in suboptimal stage II and IV epithelial ovarian cancer (EOC): Gynecologic Oncology Group (GOG) study # 132. Proc. Am. Soc. Clin. Oncol. 16, 352a.

    Google Scholar 

  37. National Institutes of Health Consensus Development Conference Statement. (1994) Ovarian cancer: screening, treatment, and follow-up. Gynecol. Oncol. 55, S4–14

    Google Scholar 

  38. Neijt, J. P., Engelholm, S. A., Witteveen, P. 0.,(1997) Paclitaxel (175 mg/m2 over 3 hours) with cisplatin or carboplatin in previously untreated ovarian cancer: an interim analysis. Semin. Oncol. 24(Suppl 15), S15–36-S15–39.

    Google Scholar 

  39. Ngan H., Choo Y., Cheung M.,(1989) A randomized study of high-dose versus low-dose cisplatin combined with cyclophosphamide in the treatment of advanced ovarian cancer. Chemotherapy 35, 221–227.

    PubMed  CAS  Google Scholar 

  40. Olsen, J. K., Sood, A. K., Sorosky, J. I., Anderson, B., and Buller, R. E. (1998) Taxol hypersensitivity: rapid retreatment is safe and cost effective. Gynec. Oncol. 68, 25–28.

    Google Scholar 

  41. Ozols, R. F., Thigpen, J. T., Dauplat, J.,(1993) Dose Intensity. Ann. Oncol. 4 (Suppl 4), S49 - S56.

    Google Scholar 

  42. Piccart, M. J., Bertelsen, G., Stuart, G.,(1997) Is cisplatin-paclitaxel (P-T) the standard in first-line treatment of advanced ovarian cancer (OvCa)? The EORTC-GCCG, NOCOVA, NCI-C and Scottish intergroup experience. Proc. Am. Soc. Clin. Oncol. 16, 352a.

    Google Scholar 

  43. Rowinsky, E. K., Gilbert, M. R., McGuire, W. P.,(1991) Sequences of Taxol and cisplatin: a phase I and pharmacologic study. J. Clin. Oncol. 9, 1692–1703.

    PubMed  CAS  Google Scholar 

  44. Rowinsky, E. K., and Donehower, R. C. (1995). Paclitaxel (Taxol) N. Engl. J. Med. 332, 1004–1014.

    PubMed  CAS  Google Scholar 

  45. Siddiqui, N., Boddy, A. V., Thomas, H. D.,(1997) A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer. Br. J. Cancer 75, 287–294.

    PubMed  CAS  Google Scholar 

  46. Stuart, G., Bertelsen, K., Mangioni, C.,(1998) Updated analysis shows a highly significant improved overall survival (OS) for cisplatin-paclitaxel as first line treatment of advanced ovarian cancer: mature results of the EORTC-GCCG, NOCOVA, NCIC CTG and Scottish intergroup trial. Proc. Am. Soc. Clin. Oncol. 17, 361a.

    Google Scholar 

  47. Swenerton, K., Jeffrey, J., Stuart, G.,(1992) Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 10, 718–726.

    PubMed  CAS  Google Scholar 

  48. ten Bokkel Huinink, W., Veenhof, C., Huizing, M.,(1997) Carboplatin and paclitaxel in patients with advanced ovarian cancer: a dose-finding study. Semin. Oncol. 24(Suppl 2), S2–21-S2–33.

    Google Scholar 

  49. ten Bokkel Huinink, W. W., Prove, A. M., Piccart, M.,(1994) A phase II trial with

    Google Scholar 

  50. docetaxel (Laxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group. Ann. Oncol. 5, 527–532.

    Google Scholar 

  51. Thigpen, T., Blessing, J., Ball, H.,(1990) Phase II trial of taxol as second line therapy for ovarian carcinoma: a Gynecologic Oncology Group Study. Proc. Am. Soc. Clin. Oncol. 9, 604.

    Google Scholar 

  52. Tom, V. (1997). Randomized study of cyclophosphamide, doxorubicin and cisplatin (CAP) vs single agent carboplatin in ovarian cancer patients requiring chemotherapy: interim results of ICON2. Proc. Am. Soc. Clin. Oncol. 15, 280.

    Google Scholar 

  53. Trimble, E. L., Adams, J. R, Vera, D.,(1993). Paclitaxel for platinum refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Centre 9103. J. Clin. Oncol. 11, 2405–2410.

    PubMed  CAS  Google Scholar 

  54. Trope, C. and Kristensen, G. (1997) Current status of chemotherapy in gynaecologic cancer. Semin. Oncol. 24(5 Suppl. 15), S15–1-S15–22.

    Google Scholar 

  55. Van Glabbeke, M., Vermorken, J., and Eisenhauer, E. (1997) Predictors of survival (OS) and time to progression (TTP) following second-or third-line treatment in advanced ovarian cancer (OVCA): an analysis of 714 patients (PTS) treated with paclitaxel, docetaxel or high dose epirubicin. Proc. Am. Soc. Clin. Oncol. 16, 354a.

    Google Scholar 

  56. Vermorken, J. B., ten Bokkel Huinink, W. W., Eisenhauer, E. A.,(1993) Carboplatin versus cisplatin. Ann. Oncol. 4 (Suppl 4), S41 - S48.

    Google Scholar 

  57. Wari, M. C., Taylor, H. L., Wall, M. E.,(1971) Plant anti-tumour agents VI. The isolation and structur of Taxol, a novel antileukemic and antitumour agent from Taxus brevifolia. J. Am. Chem. Soc. 93, 2325–2329.

    Google Scholar 

Lung Cancer

  1. Androulakis, N., Kourousis, C., Kakolyris, S.,(1996) First line treatment of nonsmall-cell lung cancer with docetaxel and cisplatin. Preliminary results of a phase II study. Ann. Oncol. 7 (Suppl 5), 98–99.

    Google Scholar 

  2. Belani, C. R, Aisner, J., Hiponia, D.,(1995) Paclitaxel and carboplatin with and without filgrastim support in patients with metastatic non-small cell lung cancer. Semin. Oncol. 22 (Suppl 9), 7–12.

    PubMed  CAS  Google Scholar 

  3. Belli, L., Le Chavalier, T., Gottfried, M.,(1995) Phase I-II trial of paclitaxel (Taxol) and cisplatin in previously untreated advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 14, 348.

    Google Scholar 

  4. Bonomi, R, Kim, C., Kugler, K., and Johnson, D. (1997) Results of a phase III trial comparing Taxol-cisplatin regimens to etoposide-cisplatin in non-small cell lung cancer. Lung Cancer 18 (Suppl 1), 10.

    Google Scholar 

  5. Bunn, P. A. and Kelly, K. (1995) A phase I study of carboplatin and paclitaxel in non-small cell lung cancer: a University of Colorado Cancer Center Study. Semin. Oncol. 22(suppl 9) 2–6.

    Google Scholar 

  6. Bunn, R. A. (1997) Defining the role of paclitaxel in lung cancer. Summary of recent studies and implications for future directions. Semin. Oncol. 24(Suppl 12), S12–15-S12–62.

    Google Scholar 

  7. Burris, H. Eckardt, J., Fields, S.,(1993) Phase II trials of taxotere in patients with non small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 12 335.

    Google Scholar 

  8. Carney, D. N. (1996) Chemotherapy in the management of patients with inoperable nonsmall-cell lung cancer. Semin. Oncol. 23 (Suppl 16), 71–75.

    PubMed  CAS  Google Scholar 

  9. Cole, J. T., Galla, R. J., Margues, C. B.,(1995) Phase I-II study of cisplatin and docetaxel (Taxotere) in non-small-cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 14, 357.

    Google Scholar 

  10. Cole, J. T., Galla, R. J., Rittenberg, C. N.,(1997) Defining the dose of docetaxel (Taxotere) in combination chemotherapy of non-small-cell lung cancer: preserving efficacy with lower dose regimens. Proc. Am. Soc. Clin. Oncol. 16 465a.

    Google Scholar 

  11. Creaven, P. J., Raghavan, D., Perez, R. P.,(1996) Early phase studies with paclitaxel/low-dose carboplatin in patients with solid tumors. Semin. Oncol. 23 (Suppl 16), 26–31.

    PubMed  CAS  Google Scholar 

  12. De Vore, R. F. III. Jagasia, M., Johnson, D. H. (1997) Paclitaxel by either 1-hour or 24-hour infusion in combination with carboplatin in advanced non-small cell lung cancer. Preliminary results comparing sequential phase II trieals. Semin. Oncol. 24(Suppl 12) 512–27-S12–29.

    Google Scholar 

  13. Douillard, F. U., Monnier, A., Ibrahim, N., (1995) Preliminary results of the first phase II trial of docetaxel in combination with cisplatin in patients with metastatic or locally advanced non-small cell lung cancer (NSLLC). Proc. Am. Soc. Clin. Oncol. 14, 351.

    Google Scholar 

  14. Ellis, R. A., Smith, I. C., Hardy, J. R.,(1995) Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer. Br. J. Cancer 71, 366–370.

    PubMed  CAS  Google Scholar 

  15. Fossella, F. V., Lee, J. S., Shin, D. M.,(1995) Phase II study of docetaxel for advanced or metastatic platinum refractory non small cell lung cancer. J. Clin. Oncol. 13, 643–651.

    Google Scholar 

  16. Georgiadis, M. S., Schuler, B. S., Brown, J. E.,(1997) Paclitaxel by 96-hour continuous infusion in combination with cisplatin. A phase I trial in patients with advanced lung cancer. J. Clin. Oncol. 15, 735–743.

    PubMed  CAS  Google Scholar 

  17. Giaccone. G., Postmus, R, Debruyne, C., for the EORTC LCCG (1997) Final results of an EORTC phase III study of paclitaxel versus teniposide in combination with cisplatin in advanced NSCLC. Proc. Am. Soc. Clin. Oncol. 16, 460a.

    Google Scholar 

  18. Greco F. A., Hainsworth, J. D. (1997) Paclitaxel (1-hour infusion) plus carboplatin in the treatment of advanced non-small cell lung cancer: results of a multicenter phase II trial. Semin. Oncol. 24(Suppl 12), S12–14-S12–17.

    Google Scholar 

  19. Huizing, M. T., Giaccone, G., van Wormerdam, L. J. C.,(1997) Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small cell lung cancer.

    Google Scholar 

  20. Jaakkimainen, L., Goodwin, P. J., Pater, J.,(1990) Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in non-small cell lung cancer. J. Clin. Oncol. 8, 1301–1309.

    Google Scholar 

  21. Klastersky, J., Sculier, J. P., European Lung Cancer Working Party (1995) Dose finding study of paclitaxel (Taxol) plus cisplatin in patients with non-small-cell lung cancer. Lung Cancer 12, 117–125.

    Google Scholar 

  22. Kosimidis, P., Mylonakis, N., Fountzilas, G., Samantos, C., Athonasiodis, A., and Skarlos, P., (1996) Paclitaxel and Carboplatin in inoperable non-small-cell lung cancer. Semin. Oncol. 23 (Suppl 16), 68–70.

    Google Scholar 

  23. Langer, C. J., Millenson, M., Rosvold E.,(1997) Paclitaxel (1 hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: A phase II study of the Fox Chase Cancer Center and its network. Semin. Oncol. 24(Suppl 12), S12–81-S12–88.

    Google Scholar 

  24. Miller, V. A, Rigas, J. R, Francis, P. A,(1995) Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer 75, 968–972.

    PubMed  CAS  Google Scholar 

  25. Natale, R. B. (1996) Preliminary results of a phase VII clinical trial of paclitaxel and carboplatin in non-small cell lung cancer. Semin. Oncol. 23 (Suppl 16), 51–54.

    PubMed  CAS  Google Scholar 

  26. Non-Small Cell Lung Cancer Collaborative Group. (1995) Chemotherapy in non-small cell lung cancer: a meta analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 311, 899–909.

    Google Scholar 

  27. Paesmans, M., Sculier, J. P., Libert R,For the European Lung Cancer Working Party (1996) Prognostic factors for survival in advanced non-small cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. J. Clin. Oncol. 13, 1221–1230.

    Google Scholar 

  28. Pirker, R., Kraynik, G., Zochbauer, S., Malarjeri, R., Kneussel, M., and Huber, H. (1995) Paclitaxel/cisplatin in advanced non-small-cell lung cancer (NSCLC). Ann. Oncol. 6, 833–835.

    PubMed  CAS  Google Scholar 

  29. Ramanathan, R. K., and Belani, C. P. (1997) Chemotherapy for advanced non-small cell lung cancer: past, present and future Semin. Oncol. 24, 440–454.

    PubMed  CAS  Google Scholar 

  30. Rowinsky, E. K., Flood, W. A., Santorius, S. L.,(1995) Phase I study of paclitaxel as a 3 hour infusion followed by carboplatin in untreated patients with stage IV non-small cell lung cancer. Semin. Oncol. 22 (Suppl 9), 48–54.

    PubMed  CAS  Google Scholar 

  31. Rowinsky, E. K., Chaudhry, V., Forastiere, A. A., (1993) Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. J. Clin. Oncol. 11, 2010–2020.

    PubMed  CAS  Google Scholar 

  32. Souquet, P. J., Chauvin, F., Boissell, J. P.,(1993) Polychemotherapy in advanced non-small cell lung cancer: a metaanalysis. Lancet 342, 19–21.

    PubMed  CAS  Google Scholar 

  33. von Pawel, J., Wagner, H., Niederle, N.,(1996) Phase II study of paclitaxel and cisplatin in patients with non-small-cell lung cancer. Semin. Oncol. 23 (Suppl 16), 47–50.

    Google Scholar 

  34. Zalcberg, J. R., Bishop, J. F., Millward, M.J.,(1995) Interim results of a phase II trial of docetaxel in combination with cisplatin in patients with metastatic or locally advanced non-small cell lung cancer (NSCLC). Eur. J. Cancer, 3A(Suppl 5), 1084.

    Google Scholar 

Head and Neck Cancer

  1. Dimery, I. W., Hong, W. K. (1993) Overview of combined modality therapies for head and neck cancer. J. Natl. Cancer Inst. 85, 95–111.

    PubMed  CAS  Google Scholar 

  2. Haselow, R. E., Adams, G. S.,(1983) Simultaneous cis-platinum (DDP) and radiation therapy (RT) for locally advanced unresectable head and neck cancer. Proc. ASCO 2, 160.

    Google Scholar 

  3. Weppelman, B., Wheeler, R. H.,(1991) A phase I study of prolonged infusion 5-fluorouracil and concomitant radiation therapy in patients with squamous cell cancer of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 20, 357–360.

    Google Scholar 

  4. Rooney, M., Kish, J., Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hours 5-FU and cisplatin. Cancer 55, 1123–1128.

    Google Scholar 

  5. Schneider, M., Etienne, M., (1995) Phase II trial of cisplatin, fluorouracil and pure folinic acid for locally advanced head and neck cancer: a pharmacokinetic and clinical survey. J. Clin. Oncol. 13, 1656–1662.

    PubMed  CAS  Google Scholar 

  6. Planting, A., Mulder, P.,(1997) Phase II study of weekly high-dose cisplatin for six cycles in patients with locally advanced squamous cell carcinoma of the head and neck. Eur. J. Cancer 33, 61–65.

    PubMed  CAS  Google Scholar 

  7. Forastiere, A., Metch, B.,(1992) Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J. Clin. Oncol. 10, 1245–1251.

    Google Scholar 

  8. Grose, W., Lehane, D., (1985) Comparison of methotrexate and cisplatin for patients with advanced squamous cell carcinoma of the head and neck region: a Southwest Oncology Group study. Cancer Treat. Rep. 69, 577–581.

    PubMed  CAS  Google Scholar 

  9. Taylor, S.G. IV., Murthy, A. K.,(1989) Combined simultaneous cisplatin/fluorouracil chemotherapy and split course radiation in head and neck cancer. J. Clin. Oncol. 7, 846–856.

    PubMed  Google Scholar 

  10. Department of Veteran Affairs Laryngeal Cancer Study Group (1991) Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced layngeal cancer. N. Engl. J. Med. 324, 1685–1690.

    Google Scholar 

  11. Lefebvre, J. L., Chevalier, D.,(1996) Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. J. Natl. Cancer Inst. 88, 890–899.

    PubMed  CAS  Google Scholar 

  12. Adelstein, D., Saxton, J.,(1997) A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancers: preliminary results. Head Neck Oct. 567–575.

    Google Scholar 

  13. Taylor, S., Murthy, A.,(1994) Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer. J. Clin. Oncol. 12, 385–395.

    PubMed  Google Scholar 

  14. Merlano, M., Vitale, V.,(1992) Treatment of advanced squamous-cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. N. Engl. J. Med. 327, 1115–1121.

    PubMed  CAS  Google Scholar 

  15. Shirinian, M., Weber, R.,(1994) Laryngeal preservation by induction chemotherapy plus radiotherapy in locally advanced head and neck cancer: the MD Anderson cancer center experience. Head Neck Jan/Feb. 39–44.

    Google Scholar 

  16. Slotman, G., Doolitle, C.,(1992) Preoperative combines chemotherapy and radiation therapy plus radical surgery in advanced head and neck cancer. Cancer 69, 2736–2743.

    PubMed  CAS  Google Scholar 

  17. Vokes, E., Weichselbaum, R.,(1992) Favorable long-term survival following induction chemotherapy with cisplatin, fluorouracil and leucovorin and concomitant chemoradiotherapy for locally advanced head and neck cancer. J. Natl. Cancer Inst. 84, 877–882.

    PubMed  CAS  Google Scholar 

  18. Adelstein, D., Kalish, L., (1993) Concurrent radiation therapy and chemotherapy for locally unresectable squamous cell head and neck cancer: an Eastern Cooperative Oncology Group pilot study. J. Clin. Oncol. 11, 2136–2142.

    PubMed  CAS  Google Scholar 

  19. Haselow, R., Warshaw, M.,(1990) Radiation alone versus radiation with weekly low dose cis-platinum in unresectable cancer of the head and neck. Head Neck Cancer 2, 279–281.

    Google Scholar 

  20. Dragovic, J. Doyle, T.,(1995) Accelerated fractionation radiotherapy.

    Google Scholar 

  21. Trott, K., Kummermehr, J. (1985) What is known about tumour proliferation rates to choose between accelerated fractionation or hyperfractionation? Radiother. Oncol. 3, 1–9.

    PubMed  CAS  Google Scholar 

  22. Forastiere, A., (1993) Use of paclitaxel (Taxol) in squamous cell carcinoma of the head and neck. Semin. Oncol. 20 (Suppl 3), 55–60.

    Google Scholar 

  23. Geard, C., Jones, J.,(1994) Radiation and Taxol effects on synchronized human cervical carcinoma cell. Int. J. Radiat. Oncol. Biol. Phys. 29, 565–569.

    PubMed  CAS  Google Scholar 

  24. Milas, L., Hunter, N.,(1994) Enhancement of tumor radioresponse of a murine mammary carcinoma by paclitaxel. Cancer Res. 54, 3506–3510.

    PubMed  CAS  Google Scholar 

  25. Forastiere, A. (1994) Paclitaxel (Taxol) for the treatment of head and neck cancer. Semin. Oncol. 21 (5 Suppl 8), 49–52.

    PubMed  CAS  Google Scholar 

  26. Vokes, E., Haraf, D.,(1995) The role of paclitaxel in the treatment of head and neck cancer. Semin. Oncol. 22 (5 Suppl 12), 8–12.

    PubMed  CAS  Google Scholar 

  27. Forastiere, A., Shank, D.,(1998) Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck. Cancer 82, 2270–2274.

    PubMed  CAS  Google Scholar 

  28. Castimel, G., Verweij, J.,(1994) Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann. Oncol. 5, 533–537.

    Google Scholar 

  29. Dreyfuss, A., Clark, J.,(1996) Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J. Clin. Oncol. 14, 1672–1678.

    PubMed  CAS  Google Scholar 

  30. Parker, R., Dabholkar, M.,(1993) Influence of Taxol:cisplatin sequencing on cisplatin-DNA adduct repair in human ovarian cancer cells. Proc. Am. Assoc. Cancer Res. 34, 356 (abstract 2122).

    Google Scholar 

  31. Hitt, R. Paz-Ares, L. (1997) Phase I/II study of paclitaxel/cisplatin as first-line therapy for locally advanced head and neck cancer. Semin. Oncol. 24(6, Suppl 19) S19–20-S 19–24.

    Google Scholar 

  32. Forastiere, A., Leong, T., (1997) A phase III trial of high-dose paclitaxel plus cisplatin plus G-CSF versus low-dose paclitaxel plus cisplatin in patients with advanced squamous cell carcinoma of the head and neck (HNSCC): an Eastern Cooperative Oncology Group trial. Proc. Am. Soc. Clin. Oncol. 16, 1367 (abstract).

    Google Scholar 

  33. Hussain, M., Salwen, W.,(1997) Paclitaxek. cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: a preliminary report. Semin. Oncol. 24(6, Suppl. 19), S 19–43–S 19–45.

    Google Scholar 

  34. Benasso, M., Numico, G.,(1997) Chemotherapy for relapsed head and neck cancer: paclitaxek. cisplatin, and 5-fluorouracil in chemotherapy-naive patients. A dose finding-study. Semin. Oncol. 24(6 Suppl 19), S 19–46–S 19–50.

    Google Scholar 

  35. Shin, D., Glisson, B.,(1998) Phase II trial of paclitaxel, ifofamide and cisplatin in patients with recurrent head and neck squamous cell carcinoma. J. Clin. Oncol. 16, 1325–1330.

    Google Scholar 

  36. Schoffski, P., Wanders, G.,(1996) Docetaxel and cisplatin: a highly active regimen for squamous cell carcinoma of the head and neck. Proc. ASCO 15, abstract 871.

    Google Scholar 

  37. Colevas, A., Busse, P.,(1998) Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial. J. Clin. Oncol. 16, 1331–1339.

    PubMed  CAS  Google Scholar 

Breast Cancer

  1. Anelli, A., Albuquerque, A. A., Tabacof, J.,(1997) High response rate of paclitaxel and doxorubicin as neoadjuvant chemotherapy in locally advanced breast cancer (IIIB)preliminary results. Breast Cancer Treat. 46, 75 (abstract 313).

    Google Scholar 

  2. Antman, K., Elder, J., Elias, A., (1990) High-dose cyclophosphamide, thiotepa and carboplatin intensification with autologous bone marrow support in patients with breast cancer responding to standard dose induction therapy. Proc. ASCO. 9, 10.

    Google Scholar 

  3. Berry, J., Ezzat, A., El-Warith A., (1996) Sequential taxoUplatin:pilot in metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 15, abstract 243.

    Google Scholar 

  4. Bonnefoi, H. Smith, I. E., O’Brien, M. E., Phase II study of continuous infusional 5-fluorouracil with epirubicin and carboplatin (instead of cisplatin) in patients with metastatic/locally advanced breast cancer (infusional ECarboF): a very active and well-tolerated outpatient regiman. Br. J. Cancer 73 391–396.

    Google Scholar 

  5. Browne, M. J., Kennedy, T., Cummings, F. (1996) Phase II study of sequential taxol and cisplatin for the treatment of metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 15, abstract 245.

    Google Scholar 

  6. Chan, S., Friedrichs, K., Noel, D., (1997) A randomized phase III study of Taxotere versus doxorubicin in patients with metastatic breast cancer who have failed an anthracycline containing regimen. Proc. ASCO 16, 154a.

    Google Scholar 

  7. Clemons, M., Leahy, M., Valle, J., (1997) Review of recent trials of chemotherapy for advanced breast cancer: the taxanes. Eur. J. Cancer 33, 2183–2193.

    PubMed  CAS  Google Scholar 

  8. Cocconi, G., Bisani, G., De Lisi, V., (1989). Platinum (P) and etoposide (e) as first-line chemotherapy for metastatic breast cancer (MBC). Preliminary results of a prospective randomized trial. Proc. ASCO 7, 13.

    Google Scholar 

  9. D’Andrea, G. M., and Seidman, A. D. (1997) Docetaxel and paclitaxel in breast cancer therapy: present status and future prospects. Semin. Oncol. 24, 27–44.

    Google Scholar 

  10. Dieras, V. (1997) Docetaxel in combination with doxorubicin: a phase I dose-finding study. Oncology 6, 17.

    Google Scholar 

  11. Dittrich, C., Jakesz, R., Grant, G., (1997) Preoperative paclitaxel in the first-line therapy of patients with breast cancer T 3/4, N 0–3, M 0, followed by surgery, CMF, tamoxifen and radiotherapy: Phase II trial. Proc. ASCO 16, 167.

    Google Scholar 

  12. Dombernowsky, P., (1996) Paclitaxel and doxorubicin, a highly active combination in the treatment of metastatic breast cancer. Semin. Oncol. 23, 13–18.

    PubMed  CAS  Google Scholar 

  13. Fernandez-Hidalgo, O., Gonzalez, F., Gil, A., (1989) 120-hours simultaneous infusion of cisplatin and fluorouracil in metastatic breast cancer. Am. J. Clin. Oncol. 12, 397–401.

    Google Scholar 

  14. Frazier, A., Wasserheit, C., Hochster, H. (1995). High rate of peripheral neuropathy may limit paclitaxel and cisplatin combination in women with advanced breast cancer. Proc. Am. Soc. Clin. Oncol. 14, abstract 145.

    Google Scholar 

  15. Gelmon, K. A., O’Reilly, S. E., Tolcher-A. W., (1996) Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer. J. Clin. Oncol. 14, 1185–1191.

    PubMed  CAS  Google Scholar 

  16. a. Gradisher

    Google Scholar 

  17. Honig, S. F. (1996) Treatment of metastatic disease: hormonal therapy and chemotherapy, in Diseases of the Breast ( Harris, J. R., Lippman, M. C., Morrow, M., et al., eds.), JP Lippincott, Philadelphia, pp. 669–734.

    Google Scholar 

  18. Jones, A. L., Smith, I. E., O’Brien, M. E., (1994) Phase II study of continuous infusion fluorouracil with epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer: an active new regimen. J. Clin. Oncol. 12, 1259–1265.

    Google Scholar 

  19. Kolaric, K., Vukas, D., and Protebica, V. (1988). Combination cyclophosphamide, Adriamycin and platinum (CAP) versus 5-fluorouracil, Adriamycin and cyclophosphamide as primary treatment in metastatic breast cancer: results of a prospective randomized study. Tumori 75, 132–136.

    Google Scholar 

  20. Martin, M., Diaz-Rubio, C., Casedo, A., (1992) Carboplatin: an active drug in metastatic breast cancer. J. Clin. Oncol. 10, 433–437.

    PubMed  CAS  Google Scholar 

  21. Nabbholtz, J., Thuerlimann, B., Bezwoda, W., (1977) Taxotere versus mitomycin C + vinblastine in patients with metastatic breast cancer who have failed and anthracycline containing regimen: preliminary results of a randomized phase III study. Proc. ASCO 16, 148a.

    Google Scholar 

  22. Nabholtz, J. M. (1996) Multicenter randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J. Clin. Oncol. 14, 1858–1867.

    PubMed  CAS  Google Scholar 

  23. O’Brien, M. D., Talbot, D. C., and Smith, I. E. (1993) Carboplatin in the treatment of advanced breast cancer: a phase II study using a pharmacokinetically guided dose schedule. J. Clin. Oncol. 11, 2112–2117.

    PubMed  Google Scholar 

  24. Pagani, O., Sessa, C., Martinelli, G., (1997) Dose-finding study of paclitaxel and cyclophosphamide in advanced breast cancer. Ann. Oncol. 8, 655–661.

    PubMed  CAS  Google Scholar 

  25. Pegram, M. D., Lipton, A., Hayes, D., (1998) Phase II study of receptor-enhanced chemosensitivity using recombinanr humanized anti-p185 HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol. 16, 2659–2671.

    PubMed  CAS  Google Scholar 

  26. Perez, E., Suman, J., Krook, P., (1988) Phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast cancer (MBC): a north central cancer treatment group trial. Proc. ASCO 17, 635.

    Google Scholar 

  27. Perez, E. A., and Hartman, L. C. (1996) Paclitaxel and carboplatin for advanced breast cancer. Semin. Oncol. 23 (Suppl 11), 41–45.

    PubMed  CAS  Google Scholar 

  28. Peters, W. P., Shpall, E. J., Jones, R. B., (1990) High-dose combination of cyclophosphamide (CPA), cisplatin (CDDP) and carmustine (BCNU) in bone marrow support as initial treatment for metastatic breast cancer: three-six year follow-up. Proc. ASCO 9, 10.

    Google Scholar 

  29. Radvin, P., Burris, H., Cooke, G., (1995) Phase II evaluation of docetaxel in advanced anthracycline-resistant or anthracenedione resistant breast cancer. J. Clin. Oncol. 13, 2879–2885.

    Google Scholar 

  30. Radvin, P. Valero, V., Nabholtz, J., (1996) Efficacy of a 5-day corticosteroid premedication in ameliorating Taxotere induced fluid retention. Proc. ASCO 15 124 (abstract).

    Google Scholar 

  31. Rowinsky, E. K., Gilbert, M. R., McGuire, W. P., (1991) Sequences of Taxol and cisplatin: a phase I and pharmacologic study. J. Clin. Oncol. 9, 1692–1703.

    PubMed  CAS  Google Scholar 

  32. Seidman, A. D. (1996) Chemotherapy for advanced breast cancer: a current perspective. Sem. Oncol. 23 (Suppl 2), 55–59.

    CAS  Google Scholar 

  33. Sledge, G. W. (1992) Cisplatin and platinum analogues in breast cancer. Semin. Oncol. 19, 78–82.

    PubMed  Google Scholar 

  34. Sledge, G. W., Neuberg, D., Ingle, J., (1997) Phase III trial of doxorubicin (A) vs. paclitaxel vs doxorubicin + paclitaxel (A & T) as first-line therapy for metastatic breast cancer (MBC): An intergroup trial. Proc. ASCO 16, 1.

    Google Scholar 

  35. Sledge, G. W., Roth, B. J. (1989) Cisplatin in the management of breast cancer. Semin. Oncol. 16, 110–115.

    Google Scholar 

  36. ten Vokkel Huinink, W., Prove, A., Piccart, M., (1994) A phase II trial of docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group. Ann. Oncol. 5, 527.

    Google Scholar 

  37. Valero, V., Holmes, F., Walters, R., (1995) Phase II trial of docetaxel: a new highly effective antineoplastic agent in the management of patients with anthracycline-resistant or anthracenedione-resistant breast cancer. J. Clin. Oncol. 13, 2886–2894.

    PubMed  CAS  Google Scholar 

  38. Vorobiof, D., Chasen, M., Moeken, R. (1996) Phase II trial of single agent docetaxel in previously treated patients with advanced breast cancer. Proc. ASCO 15, 120 (abstract).

    Google Scholar 

  39. Wasserheit, C., Frazein, A., Oratz-R, (1996) Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity. J. Clin. Oncol. 14, 1993–1999.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Michelle Vaughan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francisco Sapunar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Martin Gore
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. CRC Centre for Cancer Therapeutics, The Institute of Cancer Research, UK

    Lloyd R. Kelland

  2. Department of Chemistry, Virginia Commonwealth University, USA

    Nicholas P. Farrell

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer Science+Business Media New York

About this chapter

Cite this chapter

Vaughan, M., Sapunar, F., Gore, M. (2000). Clinical Experience. In: Kelland, L.R., Farrell, N.P. (eds) Platinum-Based Drugs in Cancer Therapy. Cancer Drug Discovery and Development. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-012-4_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-012-4_9

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-091-5

  • Online ISBN: 978-1-59259-012-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation